NCT05495425已完成3 期
Placebo-controlled Comparative Study of NPC-12Y Gel in Patients With Skin Lesions Associated With Tuberous Sclerosis Complex
Nobelpharma5 个研究点 分布在 1 个国家目标入组 43 人开始时间: 2022年6月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 43
- 试验地点
- 5
- 主要终点
- Improvements in angiofibroma
研究概览
简要总结
The purpose of this study is to investigate the efficacy and safety of NPC-12Y gel compared with placebo for skin lesions associated with tuberous sclerosis.
详细描述
This is a Phase 3, placebo-controlled comparative study of NPC-12Y gel in patients with skin lesions associated with tuberous sclerosis complex. Patients who meet all entry criteria for this study will apply NPC-12Y gel or placebo twice a day for 12 weeks. After the double-blind evaluation period, all patients will apply NPC-12Y gel twice a day for 52 weeks. Approximately 40 eligible patients will be enrolled
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 3 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patients 3 years old or greater at the time of informed consent
- •Patients who are diagnosed as definite diagnosis according to diagnostic criteria for tuberous sclerosis complex (International Tuberous Sclerosis Complex Consensus Conference 2012)
- •Patients with three or more reddish papules of angiofibroma ( >= 2 mm in diameter) on the face at screening tests
- •Patients who are not suitable for therapy with laser or surgery (including liquid nitrogen therapy and phototherapy) for angiofibroma, or who do not want therapy with laser or surgery
- •Patients who are being treated with Rapalimus® gel 0.2% (NPC-12G Gel 0.2%) and who are able to and agree to a withdrawal of at least 4 weeks prior to enrollment in this study.
- •Patients who (or whose guardian) give a written informed consent in understanding and willingness after having received enough explanation regarding the study participation.
排除标准
- •Patients who (or whose guardian) are hard to apply the investigational drug topically with keeping compliance
- •Patients who are hard to be taken pictures of their lesions adequately in such cases that they may not follow instruction of stillness
- •Patients with clinical findings such as erosion, ulcer and eruption on or around the lesion of angiofibroma, which may affect assessment of safety or efficacy
- •Patients with a history or complication of allergy to the component of the investigational drug (sirolimus)
- •Patients who have any infectious disease, cardiac disease, hepatic disease, pulmonary disease, renal disease, hematological disease, or malignant tumor that is considered inappropriate for participation in this clinical study.
- •Patients who have complications such as diseases unsuitable for the trial participation, for examples, uncontrolled diabetes, dyslipidemia, etc.
- •Patients who have participated in other clinical trial or clinical study, and have taken an investigational or clinical study drug within 6 months before the initial registration
- •Patients who used mTOR inhibitors (oral or injectable) other than everolimus within 4 weeks before the initial registration
- •Female patients who are pregnant, may be pregnant, or are lactating
- •Patients who cannot agree to use appropriate contraception after the date of consent to participate in the clinical study and for the duration of the clinical study (including male patients with a partner of childbearing potential)
- •Patients who have received therapy with laser or surgery (including liquid nitrogen therapy and phototherapy) to the lesion of angiofibroma within 6 months before the initial registration
- •Other patients who are considered by the investigator as unsuitable for participation in the clinical study
研究组 & 干预措施
NPC-12Y gel
Experimental
NPC-12Y gel is containing 0.2% Sirolimus
干预措施: NPC-12Y gel (Drug)
NPC-12Y placebo gel
Placebo Comparator
Placebo gel matched NPC-12Y gel
干预措施: NPC-12Y placebo gel (Drug)
结局指标
主要结局
Improvements in angiofibroma
时间窗: 12 weeks
Improvements comparing with baseline is assessed using photograph by IRC
次要结局
- Improvements in angiofibroma, color and size(12 weeks)
- Index of Facial Angiofibromas (IFA) score(12 weeks)
研究者
研究点 (5)
Loading locations...
相似试验
已完成
3 期
Phase III Trial of Topical Formulation of Sirolimus to Skin Lesions in Patients With Tuberous Sclerosis Complex (TSC)Tuberous SclerosisHypomelanotic MaculePlaqueAngiofibromaNCT02635789Nobelpharma62
已完成
1 期
Bioequivalence Study of NPC-12 (Sirolimus) Granules and TabletsBioequivalence StudyNCT03765944Nobelpharma10
撤回
3 期
Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)Relapsing-Remitting Multiple SclerosisRelapsing Forms of Multiple SclerosisNCT02428218Biogen
进行中（未招募）
3 期
A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Placebo in T2DM PatientsType 2 Diabetes MellitusNCT06254014Beijing Dongfang Biotech Co., Ltd.270
已完成
3 期
A Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate in the Treatment of Patients With COPDCOPDNCT00215436Dey345